SYK and parasitic infectious disease: Furthermore, an independent Syk inhibitor, entospletinib, which is currently in use in clinical trials for leukemia [44], also reduced IL-1β release from T. gondii-infected monocytes in a dose-dependent manner (Fig 2D), without affecting parasite infection efficiency (S2A Fig) or viability (S2B Fig).